Beam Therapeutics reported promising Phase 1/2 data for BEAM-302, demonstrating durable gene correction for AATD. See why I ...
Glaucoma Research Foundation (GRF) announced the nine recipients of its $55,000 one-year Shaffer Research Grants. "We are extremely fortunate for the ongoing and generous investment from our glaucoma ...
EMERYVILLE, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback